Activation of NF-κB/ALDH1A1 Signaling Promotes Non-Mutational Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer

Lingyu Zhang, Guibin Weng, Chunjiang Liu, Qiumei Li, Jieyu Li, Yan Wang, Chuanzhong Huang, Wanzun Lin, Dali Zheng, Yunbin YeResearch Square 2025 · DOI

This research paper, recently published on the Research Square preprint platform, investigates a major hurdle in lung cancer treatment: how tumors learn to "ignore" targeted therapies without actually mutating their DNA.

TL;DR

Researchers have identified that long-term treatment with EGFR inhibitors triggers a "survival mode" in lung cancer cells by activating the NF-κB/ALDH1A1 signaling pathway. This pathway turns ordinary cancer cells into resilient, stem-like cells that resist treatment; however, this resistance can be reversed by combining standard therapies with inhibitors like Disulfiram or EGCG.

What Problem Does This Paper Address?

Non-Small Cell Lung Cancer (NSCLC) patients with specific EGFR mutations often respond remarkably well to drugs called Tyrosine Kinase Inhibitors (TKIs), such as osimertinib. Unfortunately, the cancer almost inevitably develops resistance.

While about half of these cases are caused by new genetic mutations (the "lock" changes so the "key" no longer fits), roughly one-third of patients develop resistance through "non-mutational" pathways. In these cases, the cancer cells undergo a phenotypic shift, becoming more like stem cells—hardier, more versatile, and essentially "immune" to the drugs. The molecular "wiring" behind this shift has remained largely a mystery, leaving clinicians with few options once first-line TKIs fail.

Methods

The authors employed a sophisticated multi-model approach to bridge the gap between the lab bench and the clinic:

  • Lung Cancer Organoids (LCOs): Instead of just using flat cell cultures, they grew 3D "mini-tumors" derived directly from patient tissues, which better mimic human biology.
  • Resistant Cell Line Engineering: They created "R-PC9" cells by exposing standard lung cancer cells to escalating doses of three different TKIs (erlotinib, afatinib, and osimertinib) over six months.
  • Transcriptomics (Smart-seq2 & RNA-seq): They sequenced the RNA of sensitive vs. resistant cells to find which genes were being "turned up."
  • Functional Assays: They used CRISPR-like silencing (shRNA) and overexpression to prove that specific genes (RELA and ALDH1A1) were the actual drivers of resistance.
  • In Vivo Models: They validated their findings in both standard mouse xenografts and Patient-Derived Orthotopic Xenografts (PDOX), where patient tumor cells are implanted into the corresponding organ in mice.

Datasets

The study utilized several key data sources:

  • Patient Samples: Surgical lung cancer tissues from Fujian Cancer Hospital used to establish LCOs and PDOX models.
  • Cell Lines: Human NSCLC lines H1650, PC-9, and H1975.
  • Sequencing Data: Newly generated Whole-Exome Sequencing (WES) to confirm the absence of new mutations and RNA-seq/Smart-seq2 data to identify differentially expressed genes (DEGs).

Key Insights and Ideas

  • The "Stemness" Shield: Resistant cells showed a marked increase in ALDH1A1, a known marker for cancer stem cells. This suggests that resistance isn't just a survival tactic; it’s a fundamental identity crisis where the cell reverts to a more primitive, drug-resistant state.
  • NF-κB as the Master Switch: The researchers found that the protein RELA (part of the NF-κB complex, usually associated with inflammation) directly binds to the promoter of the ALDH1A1 gene. Essentially, the stress of TKI treatment "flips the switch" on NF-κB, which then orders the production of ALDH1A1.
  • Non-Mutational Proof: Using Whole-Exome Sequencing, the team proved that their resistant LCOs and cell lines hadn't acquired new mutations like T790M. This confirms that the resistance was purely a result of altered gene signaling, not genetic evolution.

Key Results

  • Resistance Magnitude: The resistant organoids (LCOs/OR) were 7 to 12 times more resistant to osimertinib than their parental versions.
  • Direct Regulation: Chromatin Immunoprecipitation (ChIP) assays confirmed that RELA physically attaches to the ALDH1A1 DNA, proving a direct regulatory link.
  • Synergy in Mice: Combining osimertinib with Disulfiram (an old drug used to treat alcoholism that also inhibits ALDH1A1) or EGCG (a compound in green tea that inhibits NF-κB) significantly shrank tumors in mice compared to using TKIs alone.
  • Clinical Correlation: In samples from patients who had failed TKI therapy, the researchers found that RELA and ALDH1A1 were "co-localized"—they were both active in the same parts of the tumor, supporting the lab findings.

Limitations and Future Work

While the study provides a clear pathway for resistance, some questions remain:

  • The Upstream Trigger: While we now know NF-κB activates ALDH1A1, it is still unclear exactly how EGFR inhibition triggers NF-κB in the first place. Mapping those intermediate steps is a likely next step.
  • Drug Repurposing: While Disulfiram and EGCG showed promise, they may not be the most potent or stable options for human patients. The authors suggest this pathway is a "therapeutic target," implying a need for more specialized inhibitors.
  • Broadness of Mechanism: It remains to be seen if this specific NF-κB/ALDH1A1 axis is the dominant pathway for all non-mutational resistance or just a specific subset of patients.

Summary updated

Abstract

<title>Abstract</title> This study investigates the molecular mechanisms underlying acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC). First, we utilized NSCLC cells, lung cancer organoids (LCOs), xenograft tumor, and patient-derived orthotopic xenografts tumor models to establish TKI resistance. Their stem cell-like properties, drug sensitivity, tumor formation in vitro and in vivo and transcriptomic profiles were analyzed. The differentially expressed genes related to TKI resistance and associated pathways were identified. Functional experiments, including gain- and loss-of-function assays, dual-luciferase reporter analysis, chromatin immunoprecipitation, Western blot, and RT-qPCR, revealed the roles of NF- κ B/ALDH1A1 signaling in acquired resistance. Compared to the parental cells and LCOs, the TKI-resistant R-PC9 and LCO/R exhibited increased RELA phosphorylation, higher frequency of ALDH1 + cells, enhanced sphere formation. ALDH1A1 over-expression promoted sphere formation and enhanced resistance to TKIs while ALDH1A1 or RELA silencing had opposite effects. Furthermore, RELA activation enhanced ALDH1A1 activity, and pharmacological inhibition of either NF- κ B or ALDH1A1 activity enhanced the sensitivity to TKIs both in vitro and in vivo. These findings indicated that aberrant activation of the NF- κ B/ALDH1A1 signaling promoted non-mutational resistance to EGFR-TKIs and provided a therapeutic target for EGFR-resistant NSCLC.
BibTeX
@inproceedings{zhang2025activation,
  author = {Lingyu Zhang and Guibin Weng and Chunjiang Liu and Qiumei Li and Jieyu Li and Yan Wang and Chuanzhong Huang and Wanzun Lin and Dali Zheng and Yunbin Ye},
  title = {{Activation of NF-κB/ALDH1A1 Signaling Promotes Non-Mutational Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer}},
  booktitle = {Research Square},
  year = {2025},
  doi = {10.21203/rs.3.rs-6132050/v1},
}
Figure